Dow, S&P 500, Nasdaq climb with Wall Street set to wrap up volatile week

🚚 J.B. Hunt Transport stock rallying into earnings, what to expect

J.B. Hunt’s stock is trading 0.91% higher today as the company prepares to report fourth-quarter 2025 results after the market closes this evening.

The quarter provides the first test of whether cost actions that drove a 21% earnings surprise in the third quarter can persist through year-end seasonality, or whether the outperformance was a one-quarter timing benefit.

Consensus sits at $1.78 in earnings per share and $3.09 billion in revenue, both implying modest top-line pressure offset by margin improvement.

The setup creates asymmetric risk. A beat would require sustained cost leverage despite choppy volumes, while a miss would most likely stem from insurance, wage, or equipment inflation overwhelming the seasonal mix. AskTraders reports.


🛢️ Chevron stock price hits new high amid Venezuela expansion hopes

Chevron Corporation’s stock surged to a new 52-week high yesterday, driven by optimism around a potential expansion of its operations in Venezuela.

The energy giant’s share price reached $169.37 during the session before closing at $167.24, marking a 2.06% gain for the day and an 11.64% increase over the past month.

The primary driver behind the move is a rise in oil prices, along with expectations of an expanded license from the US government that could allow Chevron to significantly increase oil production and exports from Venezuela.

Chevron is expected to be among the first companies to receive approval from the US government to resume business activities in Venezuela. AskTraders reports.


🧬 ImmunityBio clocks 700% revenue surge in 2025 from lead bladder cancer drug

ImmunityBio shares are up on Thursday as the company reports continued execution and sales momentum, with a significant increase in preliminary net product revenue.

ImmunityBio announced preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a remarkable 700% increase year over year.

Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer carcinoma in situ.

For the fourth quarter of 2025, the company reported revenue of about $38.3 million, surpassing the previous quarter’s $31.8 million, marking a 20% quarter over quarter increase and a 431% year over year increase. Benzinga reports.


👁️ PainReform’s LayerBio drop-less OcuRing-K delivery platform shows favorable safety profile

PainReform Ltd., a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, announced safety data supporting the continued development of the OcuRing-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery.

The development program included a series of preclinical rabbit studies evaluating ocular tolerability, biocompatibility, and tissue response, along with a Phase I clinical study in patients undergoing cataract surgery.

Collectively, these studies demonstrated a favorable safety profile for the platform, supporting its advancement toward later-stage development. Globe Newswire reports.


🚕 WeRide’s fleet surpasses 1,000 autonomous vehicles with driverless operations in three cities

Chinese robotaxi company WeRide Inc. has announced an expansion of its global autonomous cab fleet as part of its broader growth push.

In a post on the social media platform X on Thursday, the company said it has reached 1,023 robotaxis globally. WeRide also confirmed it has achieved driverless operations in Beijing, Guangzhou, and Abu Dhabi.

The company said the milestone marks an important step toward its vision of deploying tens of thousands of robotaxis by 2030. Benzinga reports.


🛰️ AST SpaceMobile stock eyes third straight weekly gain as ‘Golden Dome’ defense buzz grows

AST SpaceMobile stock is on track to close the week in the green, marking its third straight week of gains as retail traders and investors point to a potential “Golden Dome” defense opportunity.

The stock surged nearly 6% in premarket trading on Friday and would log its third consecutive daily gain if momentum holds during regular market hours.

On Thursday, the Missile Defense Agency made an additional 340 awards under the Scalable Homeland Innovative Enterprise Layered Defense program, with multiple awards and a ceiling of $151 billion. Stockwits reports.


🏗️ Springview extends rally for second session after eye-popping 674% one-day surge

A key partnership announcement woke up the sleepy stock. The residential builder unveiled a memorandum of understanding with China-based Jiangsu GSO New Energy Technology to integrate rooftop solar and energy-efficiency solutions into residential projects in Singapore.

Under the plan, GSO will offer product solutions, engineering support, and technical expertise, while Springview will ensure project delivery, regulatory coordination, and homeowner engagement within Singapore.

To be sure, it is not a binding deal, and Springview did not share revenue or expectations.

On Stocktwits, retail sentiment shifted to extremely bullish from bearish the previous day, with extremely high message volume. Stockwits reports.


⚡ SMR stock back in focus as Trump urges big tech to share power costs and help build plants

NuScale Power’s stock jumped nearly 2% in overnight trading as a renewed push by the Trump administration asking technology giants to share the burden of rising power prices and the construction of new plants appeared to ease investor concerns.

The company’s stock closed down 4.7% on Thursday, marking its worst session since December, as worries around its pre-revenue growth stage have lingered over recent months.

Trump’s call for technology companies to help finance and build new power plants could come as a relief for NuScale, which has yet to turn a profit and has been relying on its partner ENTRA1 Energy to develop a fleet of power plants. Stockwits reports.

*Estimate and Actual numbers represent Earnings Per Share in US Dollars


WIT: Wipro
Q3 2026
Before Market Open
Estimate: 0.040
Actual: N/A

PNC: PNC Finl Servs Gr
Q4 2025
Before Market Open
Estimate: 4.220
Actual: N/A

RF: Regions Finl
Q4 2025
Before Market Open
Estimate: 0.610
Actual: N/A

“The greatest enemy of a good plan is the dream of a perfect plan.”

– Carl von Clausewitz

Sourced in: Strategy Quotes – Britannica.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.